Repeat Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors: A NET Center of Excellence Experience.

Introduction: The available data for the safety and efficacy of repeat peptide receptor radionuclide therapy (PRRT) are almost exclusively from European centers. We present an updated experience with repeat PRRT in a cohort of US patients with neuroendocrine tumors (NETs) at our NET center of excellence.

Methods: We used our single-center longitudinal NET registry to identify patients who had been previously treated with at least one dose of PRRT (PRRT 1, either Lu DOTATATE or Y DOTATOC) and following radiographic disease progression were re-treated with a second course of PRRT (PRRT 2).

Lost in translation: evaluating the readability of online patient information for neuroendocrine tumors.

Introduction: Recent data show that many patients with NETs do not receive sufficient education regarding their diagnosis and therefore tend to search for information or literature independently. We sought to assess the readability of OPI for neuroendocrine tumors and to analyze compliance to NIH guidelines for OPI (readability level 8th grade or below).

Methods: We performed a Google search to compile a list of the top ten OPI websites using the search term "neuroendocrine tumor".